0001209191-19-049169.txt : 20190911 0001209191-19-049169.hdr.sgml : 20190911 20190911162907 ACCESSION NUMBER: 0001209191-19-049169 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190909 FILED AS OF DATE: 20190911 DATE AS OF CHANGE: 20190911 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Davidson David CENTRAL INDEX KEY: 0001578696 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35966 FILM NUMBER: 191088583 MAIL ADDRESS: STREET 1: C/O BLUEBIRD BIO, INC. STREET 2: 60 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: bluebird bio, Inc. CENTRAL INDEX KEY: 0001293971 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 60 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 339-499-9300 MAIL ADDRESS: STREET 1: 60 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Genetix Pharmaceuticals Inc DATE OF NAME CHANGE: 20040616 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-09-09 0 0001293971 bluebird bio, Inc. BLUE 0001578696 Davidson David C/O BLUEBIRD BIO, INC. 60 BINNEY STREET CAMBRIDGE MA 02142 0 1 0 0 Chief Medical Officer Common Stock 2019-09-09 4 M 0 3000 50.51 A 34616 D Common Stock 2019-09-09 4 S 0 3000 100.1133 D 31616 D Common Stock 2019-09-10 4 M 0 2060 50.51 A 33676 D Common Stock 2019-09-10 4 S 0 2060 100.1573 D 31616 D Stock Option (right to buy) 50.51 2019-09-09 4 M 0 3000 0.00 D 2026-03-01 Common Stock 3000 11685 D Stock Option (right to buy) 50.51 2019-09-10 4 M 0 2060 0.00 D 2026-03-01 Common Stock 2060 9625 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 10, 2019. The range in prices for the transaction reported on this line was $100.00 to $100.36. The average weighted price was $100.1133. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. The range in prices for the transaction reported on this line was $100.00 to $100.47. The average weighted price was $100.1573. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. This option vests over a four-year period, at a rate of twenty-five percent (25%) on January 4, 2017 and in 36 equal monthly installments thereafter. /s/ Jason F. Cole, Attorney-in-Fact 2019-09-11